SA
Go ProLog In
BMRN
OverviewIntelligenceChart
Q3 2026 EPS Estimate
$0.99
Reports after close
Revenue Estimate
$934M

Analyst Sentiment

Wall St. Consensus
Buy
30 analysts·High coverage
68
Score
22 Buy (73%)8 Hold (27%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
2273%
Hold
827%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$50.00
-7.6%
Consensus
$95.00
+75.6%
Bull
$120.00
+121.9%
12-Month Target Range30 analysts
$50.00$95.00$120.00
Current $54.09Consensus
Current Price
$54.09
Upside to Consensus
$40.91

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

No analyst estimates available

Earnings Surprises

Earnings surprise history unavailable.

Recent Analyst Actions

May 22, 2026Canaccord Genuity
BioMarin price target lowered to $111 from $116 at Canaccord
Target:$111.00
+105.2%from $54.10
May 18, 2026Leerink Partners
BioMarin price target lowered to $62 from $64 at Leerink
Target:$62.00
+24.8%from $49.67
May 18, 2026H.C. Wainwright
BioMarin price target lowered to $50 from $55 at H.C. Wainwright
Target:$50.00
-0.3%from $50.15
May 11, 2026Goldman Sachs
BioMarin reinstated with a Neutral at Goldman Sachs
Target:$69.00
+27.6%from $54.06
May 5, 2026Evercore ISI
BioMarin price target raised to $120 from $110 at Evercore ISI
Target:$120.00
+120.8%from $54.36
May 5, 2026Tudor Pickering
BioMarin price target lowered to $82 from $94 at Bernstein
Target:$82.00
+47.9%from $55.46
Apr 27, 2026Morgan Stanley
BioMarin resumed with an Overweight at Morgan Stanley
Target:$120.00
+125.6%from $53.18
Mar 12, 2026Jefferies
Jefferies Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN): "data looks viable and is a positive sign"
Target:$103.00
+72.1%from $59.86
Mar 3, 2026Barclays
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Barclays
Target:$105.00
+75.8%from $59.74
Mar 2, 2026Loop Capital Markets
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Freedom Capital Markets
Target:$105.00
+73.6%from $60.47
Feb 26, 2026Canaccord Genuity
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $104 at Canaccord
Target:$104.00
+72.6%from $60.26
Feb 24, 2026Oppenheimer
BioMarin price target lowered to $95 from $98 at Oppenheimer
Target:$95.00
+51.0%from $62.92
Feb 24, 2026Stifel Nicolaus
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $68 at Stifel
Target:$68.00
+10.7%from $61.44
Feb 18, 2026Wells Fargo
BioMarin price target raised to $75 from $70 at Wells Fargo
Target:$75.00
+25.1%from $59.95
Feb 6, 2026Piper Sandler
BioMarin price target lowered to $84 from $122 at Piper Sandler
Target:$84.00
+47.0%from $57.15
Jan 20, 2026Canaccord Genuity
BioMarin upgraded to Buy from Hold at Canaccord
Target:$98.00
+79.5%from $54.59
Dec 23, 2025Truist Financial
BioMarin price target raised to $100 from $80 at Truist
Target:$100.00
+68.7%from $59.28
Dec 22, 2025H.C. Wainwright
BioMarin price target raised to $60 from $55 at H.C. Wainwright
Target:$60.00
-1.9%from $61.15
Dec 3, 2025Leerink Partners
BioMarin downgraded to Market Perform from Outperform at Leerink
Target:$60.00
+11.3%from $53.89
Nov 3, 2025Tudor Pickering
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered at Bernstein Amid 'Tough NT Setup'
Target:$88.00
+64.3%from $53.57
Nov 3, 2025Bernstein
BioMarin price target lowered to $88 from $95 at Bernstein
Target:$88.00
+64.3%from $53.57
Oct 28, 2025RBC Capital
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $66 at RBC Capital
Target:$66.00
+21.7%from $54.25
Oct 28, 2025Stifel Nicolaus
BioMarin price target lowered to $73 from $91 at Stifel
Target:$73.00
+32.8%from $54.97
Oct 28, 2025Truist Financial
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered at Truist; 'Competitive Pressures Mounting'
Target:$80.00
+46.8%from $54.48
Oct 28, 2025Morgan Stanley
BioMarin price target lowered to $98 from $104 at Morgan Stanley
Target:$98.00
+78.1%from $55.04

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance